KRAS and colorectal carcinoma: For example, a mutation in the E3 ligase RNF43 led to a sensitivity of CRC organoids to porcupine inhibitors, and PDOs with mutations in TP53 were extremely resistant to the MDM2 inhibitor nutlin-3a, while KRAS-mutant organoids were resistant to ERBB inhibitors.